Floatz logo

Idarubicine

Leukemia, Myeloid

M.D. Anderson Cancer CenterPhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Leukemia, Myeloid cohort.

Asset / SponsorPhaseRating
Fludarabine
M.D. Anderson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Actinium Pharmaceuticals
Phase 2/3BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 2BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 3BB
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2BB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →